Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Grace Hettich"'
Autor:
Michal Sarfaty, Karissa Whiting, Min Yuen Teo, Chung‐Han Lee, Vanessa Peters, Jennifer Durocher, Ashley M. Regazzi, Asia S. McCoy, Grace Hettich, Achim A. Jungbluth, Hikmat Al‐Ahmadie, Irina Ostrovnaya, Joshua Chaim, Dean F. Bajorin, Jonathan E. Rosenberg, Gopa Iyer, Samuel A. Funt
Publikováno v:
Cancer Medicine, Vol 10, Iss 3, Pp 1074-1083 (2021)
Abstract Background Immune checkpoint blockade has made a significant impact on the clinical outcomes of patients with metastatic urothelial carcinoma (UC). However, evidence for this approach in patients with non‐UC of the urinary tract is limited
Externí odkaz:
https://doaj.org/article/3267ae311acc413783cc2529ba317882
Autor:
Samuel A. Funt, Michael Lattanzi, Karissa Whiting, Hikmat Al-Ahmadie, Colleen Quinlan, Min Yuen Teo, Chung-Han Lee, David Aggen, Danielle Zimmerman, Deaglan McHugh, Arlyn Apollo, Trey D. Durdin, Hong Truong, Jeffrey Kamradt, Maged Khalil, Bradley Lash, Irina Ostrovnaya, Asia S. McCoy, Grace Hettich, Ashley Regazzi, Marwah Jihad, Neha Ratna, Abigail Boswell, Kaitlyn Francese, Yuanquan Yang, Edmund Folefac, Harry W. Herr, S. Machele Donat, Eugene Pietzak, Eugene K. Cha, Timothy F. Donahue, Alvin C. Goh, William C. Huang, Dean F. Bajorin, Gopa Iyer, Bernard H. Bochner, Arjun V. Balar, Amir Mortazavi, Jonathan E. Rosenberg
Publikováno v:
J Clin Oncol
PURPOSE Neoadjuvant gemcitabine and cisplatin (GC) followed by radical cystectomy (RC) is standard for patients with muscle-invasive bladder cancer (MIBC). On the basis of the activity of atezolizumab (A) in metastatic BC, we tested neoadjuvant GC pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::611a8910c42cbcab86adb0b2211563d4
https://pubmed.ncbi.nlm.nih.gov/35609220
https://pubmed.ncbi.nlm.nih.gov/35609220
Autor:
Grace Hettich, Samuel A. Funt, Min Yuen Teo, Gopa Iyer, Joshua Chaim, Jonathan E. Rosenberg, Ashley Marie Regazzi, Asia S. McCoy, Achim A. Jungbluth, Chung-Han Lee, Hikmat Al-Ahmadie, Michal Sarfaty, Vanessa Peters, Dean F. Bajorin, Irina Ostrovnaya, Karissa Whiting, Jennifer Durocher
Publikováno v:
Cancer Medicine, Vol 10, Iss 3, Pp 1074-1083 (2021)
Cancer Medicine
Cancer Medicine
Background Immune checkpoint blockade has made a significant impact on the clinical outcomes of patients with metastatic urothelial carcinoma (UC). However, evidence for this approach in patients with non‐UC of the urinary tract is limited. Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4076d4b3665c84de580048a7598d0198
https://doi.org/10.1002/cam4.3699
https://doi.org/10.1002/cam4.3699
Autor:
Hikmat Al-Ahmadie, Joshua Chaim, Ashley Marie Regazzi, Phillip Wong, Gopa Iyer, Jonathan E. Rosenberg, Jedd D. Wolchok, Moshen Abu-Akeel, Karan Jatwani, Asia S. McCoy, Samuel Funt, Min Yuen Teo, Chung-Han Lee, Michelle Makris, Irina Ostrovnaya, Jeremy C. Durack, Grace Hettich, Deaglan Joseph McHugh, Dean F. Bajorin, Taha Merghoub
Publikováno v:
Journal of Clinical Oncology. 37:4559-4559
4559 Background: GC has a high overall response rate (ORR) but a high relapse rate in pts with untreated mUC. Inhibition of programmed death-ligand 1 (PD-L1) with A can lead to long-term survival, but single-agent ORR is modest. We report the outcome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab6c471d2abd131f56e462cab9f80ddc
https://doi.org/10.1200/jco.2019.37.15_suppl.4559
https://doi.org/10.1200/jco.2019.37.15_suppl.4559
Autor:
Mark J. Bluth, Phillip Wong, Grace Hettich, Niamh M. Keegan, Jessica M. Clement, Samuel Funt, Brooke Elizabeth Kania, Gopa Iyer, Dean F. Bajorin, Etay Ziv, Jonathan E. Rosenberg, Katherine S. Panageas, Asia S. McCoy, Jedd D. Wolchok, Colleen Anne Maher, Suresh G. Nair Md, Margaret K. Callahan
Publikováno v:
Journal of Clinical Oncology. 37:481-481
481 Background: Overcoming resistance to anti-PD-1 therapy in UC patients (pts) is of major interest given the modest single agent response rates for pts with mUC. Herein we report the outcome of combined NIVO and IPI in pts who progressed on single
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2af3cad48637c48e6a52ed4a208c79b4
https://doi.org/10.1200/jco.2019.37.7_suppl.481
https://doi.org/10.1200/jco.2019.37.7_suppl.481
Autor:
Asia S. McCoy, Samuel Funt, Jedd D. Wolchok, Gopa Iyer, Phillip Wong, Etay Ziv, Jonathan E. Rosenberg, Grace Hettich, Mark J. Bluth, Jessica M. Clement, Margaret K. Callahan, Brooke Elizabeth Kania, Dean F. Bajorin
Publikováno v:
Journal of Clinical Oncology. 35:384-384
384 Background: Programmed cell death –1 (PD-1) and its ligand (PD-L1) serve as checkpoints that regulate the interaction between the immune system and tumors. Antibodies blocking PD-1 or PD-L1 enhance antitumor activity in pts with UC. NIVO, a PD-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::87b44537bd2f85fca82bd5c9c5067810
https://doi.org/10.1200/jco.2017.35.6_suppl.384
https://doi.org/10.1200/jco.2017.35.6_suppl.384